Characteristics and management of sublingual allergen immunotherapy in children with allergic rhinitis and asthma induced by house dust mite allergens by Florence Trebuchon et al.
Trebuchon et al. Clinical and Translational Allergy 2014, 4:15
http://www.ctajournal.com/content/4/1/15RESEARCH Open AccessCharacteristics and management of sublingual
allergen immunotherapy in children with allergic
rhinitis and asthma induced by house dust mite
allergens
Florence Trebuchon1,4*, Michèle Lhéritier-Barrand2, Marie David2 and Pascal Demoly3Abstract
Background: Allergen immunotherapy is a recognised intervention in patients with allergies not responding to
standard pharmacotherapy or in whom pharmacotherapy is contraindicated. We describe the sublingual
immunotherapy (SLIT) regimens used in children and adolescents with house dust mite (HDM) respiratory allergies
in France and assess the efficacy and safety of this treatment.
Methods: This was a sub-analysis of paediatric patients included in a previous retrospective, observational,
multicentre study. Inclusion criteria were: age 5–17 years; respiratory allergy and proven sensitisation to HDM; at
least 2 years follow-up after SLIT initiation. The following data were recorded at SLIT initiation: clinical characteristics;
sensitisation profile; concomitant symptomatic medications; details of SLIT protocol. During follow-up and at the
end of treatment the following data were recorded: any changes to SLIT treatment; any changes to symptomatic
medications; symptom progression; adverse events. SLIT efficacy, patient compliance and satisfaction, and safety
were assessed.
Results: 736 paediatric patients were included in this analysis. Most patients (95.5%) had allergic rhinitis, which was
moderate to severe persistent in 62.8%. Allergic asthma was present in 64.0% and was mild to moderate persistent
in 52.7% of these patients. The majority of patients had rhinitis with asthma (59.5%). Three-hundred and seventy five
(62.3%) patients were polysensitised. Compliance was good in 86.5% of patients and SLIT was effective in 83.8%.
Symptoms of rhinitis and asthma were improved in 64.6% and 64.3% of patients, respectively. A decrease in symptomatic
medication was observed following SLIT initiation in patients with rhinitis and/or asthma. SLIT was well tolerated with
mainly local reactions reported.
Conclusions: HDM SLIT appears to be effective in children and adolescents with rhinitis and/or asthma due to HDM
allergens, with no tolerability issues and similar benefits as in adults.
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Allergen immunotherapy (AIT) is a recognised interven-
tion in patients with allergies not responding to standard
pharmacotherapy or in whom pharmacotherapy is contra-
indicated [1,2]. AIT was initially administered subcutane-
ously (SCIT), but this treatment is time-consuming and* Correspondence: ftrebuchon@free.fr
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article, unless otherwise stated.can be uncomfortable with frequent local adverse events
such as injection site swelling [3]. Sublingual immunother-
apy (SLIT) has been developed as an alternative route of
administration with the aim of improving safety and toler-
ability. Comparisons of SLIT versus SCIT do not demon-
strate superior efficacy of either administration route [4-6]
although further comparative data would be valuable. In
children, the convenience of home administration and tol-
erability of daily treatment are perhaps more importanttral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
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as opposed to SCIT.
Recent systematic reviews of randomised, placebo-
controlled trials of SLIT in adults and children show
that SLIT is effective at reducing the symptoms of aller-
gic rhinitis and asthma and is a safe route of administra-
tion [3,6-8]. Furthermore, symptomatic medication use
for allergic rhinitis and asthma decreases significantly in
patients who use SLIT [7-9]. These findings are consist-
ent with the reduced use of rescue medication reported
in a meta-analysis of SLIT for respiratory allergies caused
by house dust mite (HDM) allergens [10]. Studies indicate
that SLIT has similar efficacy in children and adults [8,11]
and favourable adherence rates have been reported for
SLIT in children, suggesting the “real-life” viability of this
form of treatment [12,13].
The 2010 revision of the allergic rhinitis and its impact
on asthma (ARIA) guidelines recommends SLIT for chil-
dren with allergic rhinitis due to pollen but, because of
poor evidence, SLIT was not recommended for use in
children with allergic rhinitis caused by HDM [14]. Sub-
sequent studies have reported a non-significant reduc-
tion in symptoms of allergic rhinitis and asthma in
children with HDM allergies treated with SLIT com-
pared to placebo [15,16].
In a previous report, we described the results of a
retrospective, observational study on the SLIT regimens
used for HDM respiratory allergies in routine practice in
France and also described the treatment’s efficacy and
safety [17]. Here we present a sub-analysis of the results
for children and adolescents aged <18 years.Methods
Study design and patients
Details of the methods used in this retrospective, observa-
tional, multicentre study have been published previously
[17]. The study was carried out in 2008. Briefly, randomly
selected allergy specialists collected information on 10
patients who started treatment with HDM SLIT (five
starting therapy in 2002 and another five in 2005) and
were monitored during treatment. Inclusion criteria
were: age >5 years; respiratory allergy and proven sensi-
tisation to HDM (positive skin test or specific IgE >0.7 kUI);
at least 2 years follow-up after SLIT initiation; and detailed
medical files allowing reliable and consistent data collec-
tion. Physicians completed a case report form for each pa-
tient based on the data recorded in their medical notes.
As the study was retrospective in design it did not affect
patient management in any way.
The study was conducted in compliance with the
Declaration of Helsinki (2004), good epidemiological
study guidelines published by the Association of French
Speaking Epidemiologists, good Pharmacoepidemiologicalpractice guidelines published by the International Society
for Pharmacoepidemiology and local regulations.
Treatments
The SLIT administered in this study consisted of a standard-
ized mixture of equal proportions of D. pteronyssinus/D.
farinae extract in several concentrations (0.1, 1, 10, 100
and 300 index of reactivity (IR)/ml). In most patients, the
study medication was titrated incrementally up to a daily
maintenance dose 300 IR over 1–2 weeks.
Data collection
Data were collected retrospectively from the medical
files of each patient. At SLIT initiation, information was
collected on the patients’ clinical characteristics and sen-
sitisation profile to the most common allergens (assessed
by skin testing), any concomitant symptomatic medica-
tions being taken and details of the SLIT protocol ad-
ministered. At a series of follow-up visits and at the end
of treatment (or at the last visit) the following data were
recorded: any changes to SLIT treatment (dose alter-
ations, early termination, etc.); any changes to symptom-
atic medications; symptom progression; and any adverse
events.
Treatment efficacy, patient compliance and patient sat-
isfaction were also recorded at each follow-up visit and
overall, as perceived by the physicians.
Statistical analysis
This sub-analysis was carried out on the data from all
children and adolescents (<18 years of age) included in
the original study.
Descriptive statistics are presented as mean ± standard
deviation (SD), or n (%).
Categorical variables were compared using the Chi2
test or Fisher’s exact test and continuous variables were
compared using the Student’s t-test, non-parametric
tests (Mann–Whitney), Kruskal-Wallis test, or analysis
of variance.
All statistical analyses were performed out using SAS®
software (version 8.2; SAS Institute Inc., Cary, NY, USA)
and AdClin® software (version 3.1.1.; AdClin, Paris, France).
Written consent was obtained from patients/parents/
legal guardians in accordance with local laws.
Results
Patients
A total of 736 paediatric patients who took part in the
original study were included in this sub-analysis. The
demographic and clinical characteristics of these patients
at inclusion are summarised in Table 1. There was a
slight predominance of males (63.9%) and the mean age
was 10.02 ± 3.14 years.









Mean (±SD) 10.0 ± 3.14
5-11 (children) 497 67.5%
12-17 (adolescents) 239 32.5%
Patients with polysensitisation* 375 62.3%
Pathology of respiratory allergy
Rhinitis alone 265 36.0%
Rhinitis + asthma 438 59.5%
Asthma alone 33 4.5%
Allergic rhinitis (with or without asthma)
Disease duration (years)
n 703 95.5%
Mean (±SD) 3.57 ± 2.43
Severity (ARIA)**
Mild intermittent 57 8.1%
Moderate or severe intermittent 56 8.0%
Mild persistent 148 21.1%
Moderate or severe persistent 440 62.8%
Allergic asthma (with or without rhinitis)
Disease duration (years)
n 471 64.0%
Mean (±SD) 3.82 ± 2.91
Severity (GINA 2004)**
Intermittent 213 45.4%
Mild persistent 163 34.8%
Moderate persistent 84 17.9%
Severe persistent 9 1.9%
Symptoms
Rhinitis (with or without asthma)
Rhinorrhoea 625 89.4%
Sneezing 576 82.5%
Nasal obstruction 575 82.3%
Nasal pruritus 428 61.7%
Anosmia 13 1.9%
Asthma (with or without rhinitis)
Cough 322 68.7%
Wheezing 245 52.1%
Difficult breathing 157 33.6%
Table 1 Demographic and clinical characteristics at
treatment initiation (Continued)
Chest tightness 103 22.1%
Rhinitis and/or asthma
Ocular pruritus 188 25.7%
Teary eyes 131 17.9%
Other 84 11.7%
Categorical variables are presented as the number and percentage of patients
relative to the total population with non-missing data.
*Positive skin test to house dust mites and at least one other allergen,
calculated as percentage of patients having at least one skin test.
**Missing data, n = 2 each.
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almost two-thirds (59.5%) had both rhinitis and asthma.
The mean duration of rhinitis symptoms was 3.57 years
and the mean duration of asthma was 3.82 years.
Sensitisation profile
A total of 602 patients had undergone skin testing; 375
(62.3%) of these patients were polysensitised to HDM al-
lergens and at least one other allergen and 227 (37.7%)
were monosensitised to HDM allergens only (Table 1).
The other allergens involved in polysensitisation were
mainly grasses, birch pollen and animal dander.
Clinical symptoms
The clinical symptoms of the patients at inclusion are
shown in Table 1. The most common nasal symptoms
were rhinorrhoea, sneezing and nasal obstruction. Rhi-
norrhoea and sneezing were mostly diurnal (41.8% and
46.1% of cases, respectively). Anosmia was rare (1.9%).
In most of the patients with moderate or severe persist-
ent rhinitis (83.2%), the symptoms were troublesome,
causing sleep disruption and impacting on school, daily
activities, hobbies and sport.
The most common respiratory symptoms were cough-
ing and wheezing. Ocular symptoms (e.g. teary eyes, ocu-
lar pruritus) were less common than nasal or respiratory
symptoms and were mostly diurnal.
Symptomatic treatments at the time of initiation of HDM
SLIT and concomitant allergen immunotherapies
At the time of SLIT initiation, oral antihistamines were
prescribed for the symptomatic treatment of rhinitis to
86.9% of patients (repeat prescription in 62.5% and new
prescription in 24.3%), nasal steroids were renewed in
25.7% and newly prescribed in 18.7%, and local antihista-
mines were renewed in 5.4% and newly prescribed in
6.1%. Treatment of patients with other medications (oral
steroids, anti-leukotrienes, cromones) was uncommon
(≤3% of patients each).
In patients with asthma at SLIT initiation, oral anti-
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Figure 1 Physician-perceived efficacy of house dust mite SLIT
at the last recorded visit. A. Physicians’ overall evaluation of SLIT /
B. Symptoms of rhinitis / C. Symptoms of asthma.
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and nasal steroids were renewed in 51.3% and newly
prescribed in 13.9%. Long-acting beta-agonists (LABA)
and short acting beta-agonists (SABA) were used in
36.3% and 45.3% of patients respectively (mainly as
renewed prescriptions 27.8% and 38.7%, respectively).
Anti-leukotrienes were given to 15.8% of patients.
Other treatments for asthma (cromones, oral LABA,
oral corticoids, theophylline) were uncommon (<2% of
patients each).
Concomitant AIT (in addition to HDM SLIT) was given
to 150 of the 736 (20.4%) children. The main allergens
involved were grasses (98/150; 65.3%), birch tree pollen
(15/150; 10.0%) and animal dander (13/150; 8.7%).
Treatment regimens
The SLIT treatment regimens used in the initiation phase
comprised daily dosing in 95.6% of patients (629/658).
The mean maintenance dose was 1016.95 ± 413.79 IR/
week (n = 521) and the mean time taken to reach the
maintenance dose was 3.9 ± 5.1 weeks (n = 655). In 38.8%
of patients, SLIT treatment was still ongoing on the day of
final data collection and in 61.2% treatment had been
stopped, in most cases (54.9%) because the end of the
treatment period had been reached during the study. The
median duration of treatment was 3.1 years.
Efficacy
Physicians considered SLIT to be effective in 83.8% of pa-
tients (Figure 1). Symptoms of rhinitis were considered to
be improved in the majority of patients (64.6%) with or
without asthma and symptoms of asthma were improved
in 64.3% (Figure 1).
Changes in symptomatic medication use during
treatment
Symptomatic medication use for both rhinitis and asthma
decreased after SLIT initiation. Over one-third (223/591;
37.7%) of patients with rhinitis who received a prescrip-
tion (new or repeat) for oral antihistamines at SLIT initi-
ation stopped this treatment before the last visit and
22.8% (143/627) stopped using nasal steroids (Figure 2).
The percentages were similar in patients in whom SLIT
had been stopped or was ongoing at the time of data
collection.
Among the patients with asthma, 32.6% (129/396) of
those newly prescribed or given a repeat prescription of
oral antihistamines at SLIT initiation stopped using this
medication before the last visit. This figure was 29.0%
(119/411) for inhaled steroids, 15.2% (66/435) for LABA,
and 8.7% (36/416) for SABA (Figure 2). This profile was
similar in patients in whom SLIT had been stopped and in
those in whom SLIT was ongoing at the end of the study.Compliance
Compliance was deemed to be good or very good by the
physicians in 86.5% of patients overall. This percentage
was higher among patients in whom treatment was still
ongoing at the end of the study period (93.9%) than
among those whose treatment had been stopped (81.9%)
(Figure 3).
Satisfaction
The majority of patients overall (85.1%) were perceived
by the physicians to be satisfied or very satisfied with their
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Figure 2 Change in symptomatic medication use during SLIT. A. Symptomatic treatments for allergic rhinitis / B. Symptomatic treatments
for asthma.
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Figure 3 Patient compliance with house dust mite SLIT as perceived by the physicians.
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Figure 4 Patient satisfaction with house dust mite SLIT as perceived by the physicians.
Table 3 Data for children and adolescents compared to
those for adult patients included in the original study
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whose treatment was still ongoing at data collection.
There was no significant difference in the levels of satis-
faction between children aged 5–11 years and adolescents
aged 11–17 years (79.8% vs. 76.7%, respectively, of patients
in whom treatment was stopped were satisfied or very sat-
isfied with treatment; 94.4% vs. 96.4%, respectively, in
whom treatment was ongoing).
Safety
SLIT was well tolerated (Table 2). Only 49 of the 275 pa-
tients for whom data were available reported an adverse
event during a follow-up visit (17.8%). These were local
reactions in the majority of cases (41/46; 89.1%) (Table 2).
Discussion
This study shows that HDM SLIT is effective in the major-
ity of children and adolescents with respiratory allergiesTable 2 Tolerance to house dust mite SLIT during
treatment
Patients with at least one follow-up visit (n = 278)
Patients with at least one adverse




At least one local reaction reported 41 (89.1%)
At least one systemic reaction reported 7 (15.2%)
At least one other reaction reported# 1 (2.2%)
*Data missing, n = 3; **data missing, n = 3; #mainly pruritus.caused by HDM allergens, with high rates of patient satis-
faction, particularly among those still receiving treatment.
Symptoms of rhinitis and asthma were improved in almost
two-thirds of patients. Consequently, there was a signifi-
cant decrease in the use of symptomatic medications, con-
firming the findings of previous reports [7-9]. Compliance
was also high showing that treatment was acceptable to
both patients and their parents.
There appears to be little difference between paediatric
patients and adults in this setting since the percentage of
children and adolescents who were polysensitised to
HDM plus at least one other allergen was very similar to
that of the adult patients included in the original study
(Table 3). Furthermore, SLIT efficacy, satisfaction and
compliance were also very similar in adults and children[17]
Children/adolescents Adults
(N = 736) (N = 551)
Rhinitis 95.5% 98.2%
Asthma 64.0% 41.0%
Rhinitis + asthma 59.5% 39.0%
Rhinitis duration (years) 3.57 ± 2.43 8.97 ± 7.84
Asthma duration (years) 3.82 ± 2.91 8.75 ± 8.38
Polysensitisation 62.3% 62.8%
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similar in children, adolescents and adults. In children/
adolescents as in adults [17], the mean target mainten-
ance dose of HDM SLIT was <150 IR/day. The achieve-
ment of efficacy at such low doses may help explain the
favourable tolerability of this therapy.
It is interesting to note that although the percentage
of children and adults with rhinitis was similar, consider-
ably more children than adults had rhinitis with asthma
(59.5% vs. 39%, respectively) (Table 3). Unsurprisingly,
the mean duration of rhinitis with or without asthma at
the time of SLIT initiation was shorter in children than
in adults and this was also the case for asthma (Table 3).
However, there was no evidence that the severity of
symptoms of either disease was significantly different in
children compared to adults.
The present results reflect the findings of previous
studies indicating similar efficacy of HDM SLIT in chil-
dren and adults [3,11]. High rates of patient satisfaction
coupled with high levels of compliance (median duration
of treatment 2.9 years) indicate that SLIT is highly ac-
ceptable and that there are no practical difficulties with
administering the treatment as prescribed. Although a
universally accepted system to grade and classify the se-
verity of adverse events of SLIT has only been proposed
recently [18] and was not available when this study was
carried out, the low incidence of adverse events reported
(17.8%) and their mild and local nature indicate a lack of
tolerability issues, supporting the high degree of patient
acceptability. These aspects are particularly important
among children where compliance is a major determin-
ant for allergy treatment, especially when managed at
home. In 2007, a study of simplified once-daily SLIT in
children reported that 84% and 66% of subjects had
compliance rates >75% and >90% at 6 months, respect-
ively, compared with 85% and 69% at 3 months [13]. A
systematic review of compliance with SLIT, published a
year later, found compliance rates ranging between 75%
and 90% [19]. The main causes of non-compliance were
inconvenience and the cost of treatment [19]. The pro-
portion of children in our study reported to have good
or very good compliance (86.5%) is consistent with pre-
vious results. Overall, the available data show that chil-
dren’s compliance with SLIT is good, even in “real-life”
settings with long-term treatment administered at home.
Strengths and limitations
Our study has some limitations. First, it was retrospective
in design and was uncontrolled leading to a potential bias
in the results. Furthermore, the study population was
highly heterogeneous in terms of age, symptoms at SLIT
initiation, symptomatic medication use, etc., due to its
“real-life” setting and observational nature. Finally, the
study was not originally designed to compare the efficacyand safety of SLIT in children (5–11 years) vs. adolescents
(11–17 years) or to compare these different age groups
with adults and some data are therefore missing.
The strengths of the study include the large number of
patients included in the analysis (n = 736) and the fact
that it was carried out in a “real-life” setting, in the med-
ical surgeries of French allergy specialists. Finally, the
long duration of the study, from 2002 (first patient in-
clusion) until data collection in 2008, enabled long-term
treatment (median duration 2.9 years), follow-up and as-
sessment of SLIT efficacy and tolerance in the children
and adolescents.
This study adds to the growing evidence that SLIT is
effective in paediatric patients with respiratory allergies.
For example, a recent review found high-quality evi-
dence of medication reduction and symptom control in
children with asthma treated with HDM SLIT [20]. The
mechanism of action of SLIT has long been believed to
involve modulation of the local immune response to al-
lergens, changing the response from an allergic reaction
to immune tolerance [21]. This is attributable to the spe-
cific biology of oral antigen-presenting cells [22]. Lang-
erhans cells, myeloid dendritic cells and macrophages in
oral tissues may, in the absence of danger signals, induce
CD4+ regulatory T-cells which support tolerance [22].
Induction of anti-inflammatory immunoglobulin G and
immunoglobulin A also appears to play a role. The present
data, acquired over a long treatment period, suggest that
the effects of SLIT do not diminish over time and are not
dependent on the patient’s age.
Conclusions
This sub-analysis of the results from our original study
[17] indicates that HDM SLIT may confer similar benefits
in children and adolescents as in adults. Our results show
good efficacy with HDM SLIT, high patient acceptability
and no tolerability issues among paediatric patients. These
findings reflect the results of previous investigations and
support trials of SLIT in children and adolescents who
have failed to respond to standard pharmacotherapy or in
whom pharmacotherapy is contraindicated.
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